Tender Offer - BIOMARIN PHARMACEUTICAL INC

Form Type: SC TO-C

Filing Date: 2025-05-19

Corporate Action: Tender-offer

Type: New

Accession Number: 000119312525121891

Filing Summary: BioMarin Pharmaceutical Inc. is initiating a tender offer through its wholly-owned subsidiary, Incline Merger Sub, Inc., to acquire all outstanding common stock of Inozyme Pharma, Inc. This preliminary communication is linked to the Agreement and Plan of Merger signed on May 16, 2025. The tender offer materials will provide further detailed information including the process for shareholders to tender their shares. The acquisition is expected to enhance BioMarin's enzyme therapies portfolio by adding Inozyme's product candidate INZ-701, which targets ENPP1 Deficiency. The filing emphasizes the potential benefits of the acquisition and highlights various risks related to the execution of this transaction. The tender offer has not yet commenced, and specific materials related to the offer will be filed with the SEC upon commencement. Investors and stockholders are advised to carefully read the forthcoming documents that will contain essential information about the proposed acquisition.